Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy
- PMID: 38277757
- DOI: 10.1016/j.drup.2024.101058
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy
Abstract
Multidrug resistance (MDR) is one of the primary factors that produces treatment failure in patients receiving cancer chemotherapy. MDR is a complex multifactorial phenomenon, characterized by a decrease or abrogation of the efficacy of a wide spectrum of anticancer drugs that are structurally and mechanistically distinct. The overexpression of the ATP-binding cassette (ABC) transporters, notably ABCG2 and ABCB1, are one of the primary mediators of MDR in cancer cells, which promotes the efflux of certain chemotherapeutic drugs from cancer cells, thereby decreasing or abolishing their therapeutic efficacy. A number of studies have suggested that non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), play a pivotal role in mediating the upregulation of ABC transporters in certain MDR cancer cells. This review will provide updated information about the induction of ABC transporters due to the aberrant regulation of ncRNAs in cancer cells. We will also discuss the measurement and biological profile of circulating ncRNAs in various body fluids as potential biomarkers for predicting the response of cancer patients to chemotherapy. Sequence variations, such as alternative polyadenylation of mRNA and single nucleotide polymorphism (SNPs) at miRNA target sites, which may indicate the interaction of miRNA-mediated gene regulation with genetic variations to modulate the MDR phenotype, will be reviewed. Finally, we will highlight novel strategies that could be used to modulate ncRNAs and circumvent ABC transporter-mediated MDR.
Keywords: ABC transporter; Exosome; Multidrug resistance; Non-coding RNAs; Non-invasive biomarker.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.Expert Opin Drug Metab Toxicol. 2021 Mar;17(3):291-306. doi: 10.1080/17425255.2021.1887139. Epub 2021 Feb 22. Expert Opin Drug Metab Toxicol. 2021. PMID: 33544643 Review.
-
MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy.J Biomed Sci. 2013 Dec 20;20(1):99. doi: 10.1186/1423-0127-20-99. J Biomed Sci. 2013. PMID: 24358977 Free PMC article. Review.
-
Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.Oncotarget. 2015 Dec 29;6(42):44643-59. doi: 10.18632/oncotarget.5989. Oncotarget. 2015. PMID: 26556876 Free PMC article.
-
ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance.Drug Resist Updat. 2023 Jan;66:100905. doi: 10.1016/j.drup.2022.100905. Epub 2022 Nov 30. Drug Resist Updat. 2023. PMID: 36463807 Review.
-
Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.Drug Resist Updat. 2017 May;32:23-46. doi: 10.1016/j.drup.2017.10.003. Epub 2017 Oct 16. Drug Resist Updat. 2017. PMID: 29145976 Review.
Cited by
-
Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer.Int J Mol Sci. 2024 Sep 16;25(18):9973. doi: 10.3390/ijms25189973. Int J Mol Sci. 2024. PMID: 39337463 Free PMC article. Review.
-
MicroRNA-486-3p affects cisplatin resistance in high-grade serous ovarian cancer by regulating TMIGD2: An experimental study.Heliyon. 2024 Jul 19;10(15):e34978. doi: 10.1016/j.heliyon.2024.e34978. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39145009 Free PMC article.
-
An enzyme-responsive hydrogel functionalized with mesoporous silica nanoparticles for co-delivery of cisplatin and shRNA to overcome chemotherapy resistance in non-small cell lung cancer.RSC Adv. 2025 Jul 10;15(29):23966-23977. doi: 10.1039/d5ra03250d. eCollection 2025 Jul 4. RSC Adv. 2025. PMID: 40642471 Free PMC article.
-
Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance.J Hematol Oncol. 2025 Mar 18;18(1):32. doi: 10.1186/s13045-025-01684-4. J Hematol Oncol. 2025. PMID: 40102937 Free PMC article. Review.
-
Role of exosomal non‑coding RNAs in cancer‑associated fibroblast‑mediated therapy resistance (Review).Int J Oncol. 2025 Aug;67(2):68. doi: 10.3892/ijo.2025.5774. Epub 2025 Jul 19. Int J Oncol. 2025. PMID: 40682844 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical